Melanocortin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  • Vanni Caruso University of Tasmania
  • Biao-Xin Chai University of Michigan
  • Adrian J. L. Clark St. Bartholomew's Hospital
  • Roger D. Cone University of Michigan
  • Alex N. Eberle Universitsspital
  • Sadaf Farooqi University of Cambridge
  • Tung M. Fong Covance Inc
  • Ira Gantz Merck & Co. Inc.
  • Carrie Haskell-Luevano University of Minnesota
  • Victor J. Hruby University of Arizona
  • Kathleen G. Mountjoy University of Auckland
  • Colin Pouton University of Bath
  • Helgi Schiöth Uppsala University
  • Jeffrey B. Tatro New England Medical Center Hospital
  • Jarl E. S. Wikberg Uppsala University


Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [36]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test, whilst NDP-MSH was approved by EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.
How to Cite
Caruso, V., Chai, B.-X., Clark, A. J. L., Cone, R. D., Eberle, A. N., Farooqi, S., Fong, T. M., Gantz, I., Haskell-Luevano, C., Hruby, V. J., Mountjoy, K. G., Pouton, C., Schiöth, H., Tatro, J. B. and Wikberg, J. E. S. (2019) “Melanocortin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F38/2019.4.